Do analysts recommend BYSI or PHIO?

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, BYSI or PHIO?

BeyondSpring is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeyondSpring N/A N/A -$1.01M -$0.14 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A

Is BYSI or PHIO more profitable?

BeyondSpring's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Phio Pharmaceuticals N/A -77.34% -70.87%

Do analysts prefer TCRT or PHIO?

Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TCRT or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Phio Pharmaceuticals N/A -77.34% -70.87%

Do analysts prefer INMB or PHIO?

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,246.15%. Given Phio Pharmaceuticals' higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, INMB or PHIO?

INmune Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio INmune Bio N/A N/A -$45.93M -$1.67 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A

Is INMB or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Phio Pharmaceuticals N/A -77.34% -70.87%

Does the media prefer INMB or PHIO?

In the previous week, INmune Bio had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for Phio Pharmaceuticals. INmune Bio's average media sentiment score of 0.63 beat Phio Pharmaceuticals' score of 0.38 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend INCR or PHIO?

Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INCR or PHIO more profitable?

InterCure's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Phio Pharmaceuticals N/A -77.34% -70.87%

Does the media prefer INCR or PHIO?

In the previous week, InterCure and InterCure both had 2 articles in the media. InterCure's average media sentiment score of 0.85 beat Phio Pharmaceuticals' score of 0.38 indicating that InterCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InterCure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PHIO or MCRB more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% Seres Therapeutics N/A -130.29% -35.35%

Phio Pharmaceuticals (PHIO) Competitors

$1.04 -0.03 (-2.80%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.02 -0.02 (-1.44%)

As of 07/24/2026 07:17 PM Eastern

Compare

PHIO vs. BYSI, TCRT, INMB, INCR, and MCRB

Should you buy Phio Pharmaceuticals stock or one of its competitors? MarketBeat compares Phio Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Phio Pharmaceuticals include BeyondSpring (BYSI), Alaunos Therapeutics (TCRT), INmune Bio (INMB), InterCure (INCR), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

How does Phio Pharmaceuticals compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

BeyondSpring's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

BeyondSpring has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.89 beat Phio Pharmaceuticals' score of 0.38 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Very Positive
Phio Pharmaceuticals	Neutral

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BeyondSpring is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	-$1.01M	-$0.14	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

Summary

Phio Pharmaceuticals beats BeyondSpring on 7 of the 13 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals' return on equity of -77.34% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alaunos Therapeutics has a beta of -1.02, indicating that its share price is 202% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Alaunos Therapeutics has higher revenue and earnings than Phio Pharmaceuticals. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	$3K	15,792.89	-$4.18M	-$2.13	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Phio Pharmaceuticals' score of 0.38 indicating that Alaunos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alaunos Therapeutics	Very Positive
Phio Pharmaceuticals	Neutral

Summary

Phio Pharmaceuticals beats Alaunos Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,246.15%. Given Phio Pharmaceuticals' higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, INmune Bio had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 3 mentions for INmune Bio and 2 mentions for Phio Pharmaceuticals. INmune Bio's average media sentiment score of 0.63 beat Phio Pharmaceuticals' score of 0.38 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

INmune Bio has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Phio Pharmaceuticals' return on equity of -77.34% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

INmune Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	N/A	N/A	-$45.93M	-$1.67	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

Summary

Phio Pharmaceuticals beats INmune Bio on 8 of the 14 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to InterCure?

InterCure (NASDAQ:INCR) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Phio Pharmaceuticals has lower revenue, but higher earnings than InterCure. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$270.20M	0.20	-$10.37M	$0.03	32.20
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A

InterCure has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

InterCure's return on equity of 0.00% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Phio Pharmaceuticals	N/A	-77.34%	-70.87%

8.3% of InterCure shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 0.9% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, InterCure and InterCure both had 2 articles in the media. InterCure's average media sentiment score of 0.85 beat Phio Pharmaceuticals' score of 0.38 indicating that InterCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phio Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phio Pharmaceuticals is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

InterCure beats Phio Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Phio Pharmaceuticals (NASDAQ:PHIO) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Phio Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Phio Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 1,246.15%. Seres Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 242.05%. Given Phio Pharmaceuticals' higher possible upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Phio Pharmaceuticals' return on equity of -77.34% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Seres Therapeutics	N/A	-130.29%	-35.35%

In the previous week, Phio Pharmaceuticals and Phio Pharmaceuticals both had 2 articles in the media. Seres Therapeutics' average media sentiment score of 0.43 beat Phio Pharmaceuticals' score of 0.38 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Neutral
Seres Therapeutics	Neutral

Seres Therapeutics has higher revenue and earnings than Phio Pharmaceuticals. Seres Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Seres Therapeutics	$790K	60.90	$5.70M	-$5.17	N/A

Summary

Seres Therapeutics beats Phio Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Phio Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHIO vs. The Competition

Export

Metric	Phio Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.43M	$3.07B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-0.75	20.29	27.14	23.64
Price / Sales	N/A	485.19	517.06	88.99
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	0.56	4.13	10.28	6.07
Net Income	-$8.70M	$65.94M	$3.60B	$331.99M
7 Day Performance	0.97%	-4.16%	-1.27%	-0.63%
1 Month Performance	8.36%	-3.76%	-0.37%	-2.00%
1 Year Performance	-62.04%	9.94%	18.30%	13.62%

Phio Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHIO Phio Pharmaceuticals	4.0099 of 5 stars	$1.04 -2.8%	$14.00 +1,246.2%	-58.6%	$12.43M	N/A	N/A	10
BYSI BeyondSpring	0.1599 of 5 stars	$1.26 +1.7%	N/A	-42.6%	$51.85M	$1.75M	N/A	80
TCRT Alaunos Therapeutics	1.0721 of 5 stars	$2.12 +4.4%	N/A	-34.9%	$51.77M	N/A	N/A	40
INMB INmune Bio	1.0764 of 5 stars	$1.91 -4.0%	N/A	-41.7%	$50.90M	$50K	N/A	10	Analyst Downgrade
INCR InterCure	1.1645 of 5 stars	$0.91 -0.3%	N/A	-37.3%	$49.98M	$78.47M	30.47	350	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHIO) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. BYSI, TCRT, INMB, INCR, and MCRB

How does Phio Pharmaceuticals compare to BeyondSpring?

Summary

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Summary

How does Phio Pharmaceuticals compare to INmune Bio?

Summary

How does Phio Pharmaceuticals compare to InterCure?

Summary

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Phio Pharmaceuticals (PHIO) Competitors

PHIO vs. BYSI, TCRT, INMB, INCR, and MCRB

How does Phio Pharmaceuticals compare to BeyondSpring?

Is BYSI or PHIO more profitable?

Which has more volatility and risk, BYSI or PHIO?

Do insiders & institutionals have more ownership in BYSI or PHIO?

Does the media refer more to BYSI or PHIO?

Do analysts recommend BYSI or PHIO?

Which has better earnings and valuation, BYSI or PHIO?

Summary

How does Phio Pharmaceuticals compare to Alaunos Therapeutics?

Do institutionals and insiders have more ownership in TCRT or PHIO?

Is TCRT or PHIO more profitable?

Do analysts prefer TCRT or PHIO?

Which has more volatility & risk, TCRT or PHIO?

Which has higher valuation and earnings, TCRT or PHIO?

Does the media refer more to TCRT or PHIO?

Summary

How does Phio Pharmaceuticals compare to INmune Bio?

Do institutionals & insiders have more ownership in INMB or PHIO?

Do analysts prefer INMB or PHIO?

Does the media prefer INMB or PHIO?

Which has more risk and volatility, INMB or PHIO?

Is INMB or PHIO more profitable?

Which has preferable valuation & earnings, INMB or PHIO?

Summary

How does Phio Pharmaceuticals compare to InterCure?

Which has preferable valuation & earnings, INCR or PHIO?

Which has more risk and volatility, INCR or PHIO?

Is INCR or PHIO more profitable?

Do insiders and institutionals hold more shares of INCR or PHIO?

Does the media prefer INCR or PHIO?

Do analysts recommend INCR or PHIO?

Summary

How does Phio Pharmaceuticals compare to Seres Therapeutics?

Which has more risk and volatility, PHIO or MCRB?

Do analysts rate PHIO or MCRB?

Do insiders & institutionals have more ownership in PHIO or MCRB?

Is PHIO or MCRB more profitable?

Does the media favor PHIO or MCRB?

Which has higher valuation and earnings, PHIO or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHIO vs. The Competition

Phio Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools